当前位置: 首页 >> 检索结果
456. Oxygen With Cold Bubble Humidification Is No Better Than Dry Oxygen in Preventing Mucus Dehydration, Decreased Mucociliary Clearance, and Decline in Pulmonary Function.
作者: Michelle Lisidati Franchini.;Rodrigo Athanazio.;Luis Fernando Amato-Lourenço.;Waldir Carreirão-Neto.;Paulo Hilario Nascimento Saldiva.;Geraldo Lorenzi-Filho.;Bruce K Rubin.;Naomi Kondo Nakagawa.
来源: Chest. 2016年150卷2期407-14页
Little is known about the effects of long-term nasal low-flow oxygen (NLFO) on mucus and symptoms and how this variable is affected by dry or cold humidified gas. The aim of this study was to investigate the effects of dry-NLFO and cold bubble humidified-NLFO on nasal mucociliary clearance (MCC), mucus properties, inflammation, and symptoms in subjects with chronic hypoxemia requiring long-term domiciliary oxygen therapy.
457. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
作者: Huan-Long Liu.;Xue-Yan Chen.;Jie-Ru Li.;Su-Wen Su.;Tao Ding.;Chen-Xia Shi.;Yun-Fa Jiang.;Zhong-Ning Zhu.
来源: Chest. 2016年150卷2期353-66页
Previous meta-analyses of pulmonary arterial hypertension (PAH)-specific therapy for PAH pooled PAH-specific combination therapy and monotherapy. This flaw may threaten the authenticity of their findings.
458. ICU Telemedicine Comanagement Methods and Length of Stay.
作者: Helen A Hawkins.;Craig M Lilly.;David A Kaster.;Robert H Groves.;Hargobind Khurana.
来源: Chest. 2016年150卷2期314-9页
Studies have identified processes that are associated with more favorable length of stay (LOS) outcomes when an ICU telemedicine program is implemented. Despite these studies, the relation of the acceptance of ICU telemedicine management services by individual ICUs to LOS outcomes is unknown.
459. WITHDRAWN: Combination of NSAID and Antitussives in Treatment of URTI Related Cough: An Observational Study.
作者: Alessandro Zanasi.;Luigi Lanata.;Federico Saibene.;Francesco De Blasio.
来源: Chest. 2016年149卷4S期A538页
The Publisher regrets that this article is an accidental duplication of an article that has already been published in Eur Respir J. 46 (2015) PA3852, http://dx.doi.org/10.1183/13993003.congress-2015.PA3852. The duplicate article has therefore been withdrawn. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal.
460. Safety and Tolerability of Alveolar Type II Cell Transplantation in Idiopathic Pulmonary Fibrosis.
作者: Anna Serrano-Mollar.;Gemma Gay-Jordi.;Raquel Guillamat-Prats.;Daniel Closa.;Fernanda Hernandez-Gonzalez.;Pedro Marin.;Felip Burgos.;Jaume Martorell.;Marcelo Sánchez.;Pedro Arguis.;Dolors Soy.;José M Bayas.;José Ramirez.;Teresa D Tetley.;Laureano Molins.;Jordi Puig de la Bellacasa.;Camino Rodríguez-Villar.;Irene Rovira.;Juan José Fiblà.;Antoni Xaubet.; .
来源: Chest. 2016年150卷3期533-43页
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease with limited response to currently available therapies. Alveolar type II (ATII) cells act as progenitor cells in the adult lung, contributing to alveolar repair during pulmonary injury. However, in IPF, ATII cells die and are replaced by fibroblasts and myofibroblasts. In previous preclinical studies, we demonstrated that ATII-cell intratracheal transplantation was able to reduce pulmonary fibrosis. The main objective of this study was to investigate the safety and tolerability of ATII-cell intratracheal transplantation in patients with IPF.
|